Very disappointed by the stock market, Oncodesign turns to a fund

  • Publication publiée :4 July 2022
  • Post category:Operation
You are currently viewing Très déçue par la Bourse, Oncodesign se tourne vers un fonds
Philippe Genne (Oncodesign): "The stock market has remained consistently myopic about our long-term strategy".

Listed on Euronext Growth in April 2014, the company announced the separation of its two branches Biotech and Service, in which a fund of Edmond de Rothschild takes a majority stake before launching a takeover bid. The valuation reaches 100 million euros, compared to 63 million in market capitalization last Thursday. The biotech part will remain listed. Between Oncodesign...

Purchase Required

Ce contenu nécessite l'achat d'un accès supplémentaire.

Click Here to Check Out

Already a member? Connectez-vous ici
Share this article

Read also:

  1. HDF Energy's big ambitions go through the stock market
  2. Aelis Farma wants to go public through the front door
  3. Towards a new reform of money market funds
  4. French money market funds are characterized by quarterly cyclicality
  5. IDI sees itself as an entry point to private equity for individuals
  6. Exclusive Networks prepares its IPO